| 查看: 583 | 回复: 5 | |||
| 【有奖交流】积极回复本帖子,参与交流,就有机会分得作者 vnyh3993 的 5 个金币 ,回帖就立即获得 1 个金币,每人有 1 次机会 | |||
[交流]
IgY-Technology英文专著在Springer出版
|
|||
|
IgY-Technology: Production and Application of Egg Yolk Antibodies: Basic Knowledge for a Successful Practice, Springer Nature Group, Switzerland 近日,IgY抗体技术专著(IgY-Technology: Production and Application of Egg Yolk Antibodies: Basic Knowledge for a Successful Practice, Springer Nature Group, Switzerland. 2021. ISBN: 978-3-030-72686-7. https://www.springer.com/gp/book/9783030726867#aboutBook)在Springer出版社出版,该书是全球范围内第一部针对IgY抗体技术的系统性英文学术专著,由张小莺教授领衔主编,联合近二十个国家的四十多位学者历时多年编撰而成。 专著链接:https://www.springer.com/gp/book/9783030726867#aboutBook 该专著共18章,系统性的回顾和总结了IgY抗体技术的发展历程、技术特点和发展前沿,涉及理论基础、技术方法学及生物医药领域的研发应用。专著覆盖了IgY技术相关的各个领域,如进化视野下的IgY分子机制、受体与转运机制、免疫技术、IgY抗体的不同提取纯化策略、储存稳定性、工业化生产、在人类和兽医领域中的应用、IgY递送策略、IgY基因工程抗体制备、转基因动物开发、IgY产品报批及产业化,技术局限与创新等。 近年来,IgY抗体技术(卵黄抗体技术)不断发展,具备了相对完备统一的技术模式;不断与现代生物学技术相结合,拓展技术自生的内涵和外延;相关产品在世界范围内不断报批问世,形成了一定的产业基础。 据悉,科学出版社将与张小莺教授团队合作,在2011年中文版的基础上,适时推出IgY抗体技术中文第二版,以供中国读者和研究人员参考、交流。 图书信息 This first edited Volume on IgY-Technology, addresses the historical and dynamic development of IgY-applications. The authors cover the biological basis and theoretical context, methodological guidance, and applications of IgY-Technology. A focus is laid on the use of IgY-antibodies for prophylactic/therapeutic purposes in human and veterinary medicine. Aside from applications, the chapters also offer an evolutionary understanding of the IgY molecule, IgY receptors and practical prerequisites to produce IgY-antibodies. Guidance is given for every step of the process. Starting with an introduction to hens as a model species and including hen husbandry, hen egg-laying capacity and total IgY outcomes. Readers will also learn about immunization techniques, the advantages and limitations of different IgY extraction methods, as well as storage stability of the final product. The last part of the volume highlights hands-on aspects of applications, such as IgY delivery strategies, new methods to produce monoclonal IgY-antibodies or production of functional IgY fragments by phage-display as well as commercial exploitation of the technology. Thus, this book is a valuable resource and guide for Scientists, Clinicians and Health Product Developers in both human and veterinary medicine. 主编信息 Prof. Dr. Xiaoying ZHANG, PhD in Pharmacology (Charité Medical University Berlin), Distinguished Professor at Shaanxi Univ. of Technology (2019-present); Senior Researcher at CBMA, Univ. of Minho, Portugal (2016-present); Professor (Adjunct) at Univ. of Guelph, Canada (2017-present); Professor at Northwest Agricultural & Forestry Univ., China (2008-2018). He has been dedicated to the development, popularisation and application of IgY Technology. Ricardo S. Vieira-Pires is an Assistant Investigator at the Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Portugal. He obtained his PhD in Structural Biology (2008) at University Joseph Fourier, Grenoble, France. He is head of the Structural Biotechnology Group that studies proteins and molecular assemblies involved in key processes of bacterial and viral infectious diseases. He is particularly interested in targeting microbial surface-exposed virulent factors using antibodies. He is head of the CNC – Avian Technological Unit that explores bird immune repertoires for antibody discovery. He is engaged with academic and industry partners promoting IgY Technology-based solutions for human and veterinary medicine. Patricia M. Morgan is an Emerita Senior Lecturer at the National University of Ireland Galway (NUI Galway). Having been awarded a PhD in Biochemistry at NUI Galway, she undertook post-doctoral research at the University of Wisconsin-Madison, USA in the areas of reproductive biology and endocrinology. She has held senior positions at NUI Galway as Dean of the College of Science and Dean of Graduate Studies. In these posts, she has championed research developments within the University particularly in the areas of Biotechnology and Innovation. She has served on various national committees promoting science and is an advocate for the public understanding of science and the promotion of inclusion and diversity in academia. Rüdiger Schade started his scientific career at the Institute of Pharmacology, Charité – Universitätsmedizin in Berlin, Germany, in 1976. Since the early 1990’s, his research has been strongly focused on the development, production and application of IgY antibodies. His contributions significantly influenced the field of IgY-technology and promoted the application of this technology worldwide, particularly in Latin-America. In acknowledgement of his research efforts, he received the FISEA prize – the International Foundation for the Substitution of Animal Experimentation, Luxemburg - in 1997. |
» 猜你喜欢
生物学296求调剂
已经有10人回复
288资源与环境专硕求调剂,不限专业,有学上就行
已经有19人回复
086000生物与医药 初试274求调剂
已经有4人回复
315求调剂
已经有7人回复
288求调剂 一志愿哈工大 材料与化工
已经有11人回复
求调剂
已经有9人回复
309求调剂
已经有16人回复
322求调剂:一志愿湖南大学 材料与化工(085600),已过六级。
已经有10人回复
330分求调剂
已经有6人回复
317求调剂
已经有13人回复
» 本主题相关商家推荐: (我也要在这里推广)
» 抢金币啦!回帖就可以得到:
南宁师范大学贺益苗课题组2026年招收有机化学和材料与化工专业拟招生4-5名硕士研究生
+1/181
2026 年山东建筑大学金属增材制造方向硕士研究生调剂公告
+1/38
沈阳农业大学生物与医药专硕招收调剂生!!!!!!!!!!
+1/35
新疆碳纳米材料制备与应用重点实验室2026年招聘启事
+1/35
北京理工大学-化学与化工学院-招收2026级博士生 [申请-考核制]
+1/23
国家双一流高校-国家级青年人才课题组博士招生
+2/22
【调剂上岸】985联合培养!1007/1055/08/07等,不限专业,想联培的速来!
+1/17
南方科技大学微电子学院陈鹏教授招收2026级博士生(第二批)
+1/9
【博士招生】天津理工大学国家杰青王铁课题组招收2026年博士研究生
+1/7
0831生医工调剂本9一志愿北航生医工,338分求调剂
+1/7
国家双一流高校-国家级青年人才课题组博士招生
+1/6
武汉工程大学化学与环境工程学院招收调剂生
+1/4
广东医科大学 李雪萌教授团队 招收申请考核制博士(临床检验诊断)
+1/3
2026年江西科技师范大学Tide课题组招收化学、生物、药学、材料相关学硕或专硕调剂生
+1/3
2026年江西科技师范大学化学化工学院隋晓锋课题组招收硕士研究生调剂
+1/3
齐齐哈尔大学化学与化学工程学院招收专硕调剂
+1/2
杭州师范大学-浙江省湿地智慧监测与生态修复重点实验室团队硕士调剂公告
+1/2
三峡大学材化学院磷硅精细化工课题组招收化学类、材料类、材料与化工类硕士
+1/1
俄克拉荷马大学2026秋季博士招生 (材料, 能源, 机械)
+1/1
广东工业大学马琳教授课题组招收2026年博士
+1/1
简单回复
tzynew2楼
2021-03-10 15:57
回复
vnyh3993(金币+1): 谢谢参与
o 发自小木虫Android客户端
2021-03-10 16:44
回复
vnyh3993(金币+1): 谢谢参与
7
psylhh4楼
2021-03-13 20:33
回复
vnyh3993(金币+1): 谢谢参与
nono20095楼
2021-03-14 10:12
回复
vnyh3993(金币+1): 谢谢参与
`
2021-03-15 10:39
回复
vnyh3993(金币+1): 谢谢参与
。














回复此楼
